Horizon Therapeutics Public Limited Co (fka HZNP)

[surf1944]

7:31AM Horizon Pharma announces receipt of two additional U.S. Patent allowances for DUEXIS (HZNP) 3.41 : Co announced that it has received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 13/403,930 and U.S. Application Serial No. 13/403,923 both entitled "Stable Compositions of Famotidine and Ibuprofen" with claims that cover DUEXIS (ibuprofen and famotidine) tablets. DUEXIS is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.